Kamada vs Zhengye Biotechnology
KMDA and ZYBT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KMDA and ZYBT compare
Kamada grew revenue faster over the last twelve months (13.2% versus −37.6% for Zhengye Biotechnology).
Kamada scores higher on the StockData Score (5 against 4 for Zhengye Biotechnology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KMDA | ZYBT |
|---|---|---|
| Size and price | ||
| Share price | $8.11 | $1.43 |
| Change, 1 year | 14.5% | −33.5% |
| Change, 5 years | 28.5% | – |
| Beta (5Y) | 0.84 | 0.41 |
| Employees | 393 | 51 |
| StockData Score | ||
| Total score | 5 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 3 | 3 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 13.2% (better) | −37.6% |
| Revenue growth, 5Y average | 6.3% | – |
| Net income growth (TTM) | – | −717% |
| EPS growth, 5Y average | −1.6% | – |
| Profitability | ||
| Gross margin | 40.8% (better) | 20.5% |
| Operating margin | 14.5% (better) | −60.6% |
| Net margin | – | −60.0% |
| FCF margin | – | 10.6% |
| Return on equity | – | −26.1% |
| Return on invested capital | – | −18.1% |
| Financial health | ||
| Debt / equity | – | 0.26 |
| Net debt / EBITDA | −0.54 | – |
| Interest coverage | 26.8× (better) | −20.7× |
| Current ratio | 4.06 (better) | 1.14 |
| Piotroski F-score | – | 3 |
| Ownership | ||
| Held by institutions | 8.6% | – |
| Held by insiders | 45.3% | 90.7% |
| Insider net buying, 12 months | −$1.7M | – |
| Short interest, % of float | 0.53% | – |
Go deeper
- KMDA stock overview
- KMDA income statement
- KMDA valuation and score
- ZYBT stock overview
- ZYBT income statement
- ZYBT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.